This article by Dr. Claudia Stefanutti et al. is published in Current Pharmaceutical Design, Volume 24 , Issue 31 , 2018 BENTHAM SCIENCE PUBLISHERS Research suggests a specific treatment for Homozygous Familial Hypercholesterolaemic (HoFH) patients; combination therapy with PCSK9–inhibitors (PCSK9-I) and lipoprotein–apheresis (LA) may have synergistic effects on circulating lipid and lipoprotein levels. The relationship with the treatment regimen mentioned above...